Compare Goodyear Tire & Rubber Co (GT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Merck & Co., Inc. — how do they compare? Goodyear Tire & Rubber Co trades at $5.98 (market cap $1.75B), while Merck & Co., Inc. trades at $131.67 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 183.9× Goodyear Tire & Rubber Co's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| GT | MRK | |
|---|---|---|
Market Cap | $1.75B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $131.84 |
52-Week Low | $5.58 | $77.60 |
Enterprise Value | $9.11B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $6.03, down 6.37% over 24 hours, reflecting bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -14.37% and ROE of -63.93% as of 2025, while recent Q2 2026 earnings missed on EPS but beat revenue estimates. Cash flow improved to a net $46 million in 2025, yet debt levels remain elevated with a debt-to-asset ratio of 34.36%.
Outlook remains challenging due to volume pressures and high costs, though analyst consensus leans hold (50%) with some buy support (34.62%). Key risks include sustained losses, competitive pressures, and macroeconomic headwinds impacting tire demand, requiring careful monitoring of turnaround efforts.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
